

Supplementary Materials

Title: Elevated lipoprotein(a) levels at dialysis initiation predict cardiovascular events: a single-center, retrospective cohort study

Journal name: Renal Replacement Therapy

Authors: Motoki Ambe, MD, Keisuke Sunohara, MD, Mao Tayasu, MD, Masahiro Takanashi, MD, Yohei Kozaki, MD, Hiroshi Nagaya, MD, PhD, Shinichiro Inaba, MD, PhD

Corresponding author: Motoki Ambe, MD, Department of Nephrology, Tosei General Hospital, 160, Nishioiwake-cho, Seto City, Aichi, 489-8642, Japan. Tel: +81-0561-82-5101. Fax: +81-0561-82-9139. Email: Ambemoto@gmail.com

Lists:

Supplementary Table 1: Fine-Gray subdistribution hazard models for the association between $\text{Lp(a)} \geq 30 \text{ mg/dL}$ and CVD

Supplementary Table 2: Complete-case analysis for the association between $\text{Lp(a)} \geq 30 \text{ mg/dL}$ and CVD

Supplementary Table 3: Landmark analysis for the association between Lp(a) and CVD (0–2 years vs. 2–5 years)

Supplementary Figure 1: The landmark analysis's Kaplan–Meier survival curves (A: 0–2 years, B: 2–5 years)

Supplementary Figure 2: Restricted cubic spline curve of the association between Lp(a) and CVD

Supplementary Table 1: Fine-Gray Subdistribution Hazard Models for the association between Lp(a) $\geq$ 30 mg/dL and CVD

	sHR	95%CI	p value
Model 1	2.10	1.29-3.42	0.003
Model 2	2.30	1.40-3.80	0.001
Model 3	2.26	1.35-3.79	0.002
Model 4	2.25	1.35-3.77	0.002
Model 5	2.66	1.54-4.62	< 0.001

Model 1: Unadjusted.

Model 2: Adjusted for age and sex.

Model 3: Adjusted for Model 2 and hypertension, diabetes, history of cardiovascular disease, and statin use.

Model 4: Adjusted for Model 3 and BMI, and smoking history.

Model 5: Adjusted for Model 4 and albumin, estimated glomerular filtration rate, hemoglobin, C-reactive protein, ferritin, and urinary protein-to-creatinine ratio. Lp (a), lipoprotein(a); CVD, cardiovascular disease; sHR, subdistribution hazard ratio; CI, confidence interval.